ReviewNature reviews. Drug discovery2009
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.
Review in Nature reviews. Drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 558 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
558 citing papers in PubMed, 1,060 citations in OpenAlex.
- KCTD15 deregulation is associated with alterations of the NF-κB signaling in both pathological and physiological model systems.Scientific reports · 2021Trial
- Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.EBioMedicine · 2019Trial
- The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity.Molecular medicine (Cambridge, Mass.) · 2026Article
- Synergistic targeting of NF-κB by cinnamic and p-coumaric acids: computational and DPPH radical scavenging assessment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit.Cell reports. Medicine · 2026Article
- The alternative NF-κB RelB subunit is a novel critical sensor of lipid metabolism to promote tumor development.Cell death & disease · 2026Article
- Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.Medical oncology (Northwood, London, England) · 2026Review
- CTSZ-dependent anoikis resistance enhances malignant characters of glioblastoma via NF-κB signaling.iScience · 2026Article
- NF-κB signaling pathway mediates the anti-tumor effect of Ginsenoside Rg1 in glioblastoma.Biochemistry and biophysics reports · 2026Article
- FAM72A is associated with lung cancer proliferation and migration via the NF‑κB signaling pathway.Molecular genetics and genomics : MGG · 2026Article
- Curcumin and Cancer-Related Inflammation.Nutrients · 2026Review
- Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer.Nutrients · 2026Review
- Multidimensional single-cell analysis of the molecular characteristics and functional pathways of Regulatory T cells in the microenvironment of HR+ breast cancer.Discover oncology · 2026Article
- GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors.Biology open · 2026Article
- A double-edged sword: the role of macrophage pyroptosis-driven cytokine storm-mediated intercellular communication in tumor progression.Frontiers in immunology · 2026Review
- Article
- Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.Journal of molecular biology · 2025Review
- G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.MedComm · 2025Review
- Integrating Inflammatory and Epigenetic Signatures in IBD-Associated Colorectal Carcinogenesis: Models, Mechanisms, and Clinical Implications.International journal of molecular sciences · 2025Review
- Transcription Factors and Methods for the Pharmacological Correction of Their Activity.International journal of molecular sciences · 2025Review
498 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear factor kappaB (NF-kappaB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-kappaB and the signalling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-kappaB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-kappaB in cancer, and the possible complications and pitfalls of such an approach, are explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.